Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and ...

Share on Pinterest Research finds a new injectable form of PrEP is superior to daily oral tablets to prevent the contraction of HIV. Sara Jurado/Getty Images New research sheds light on the efficacy ...

Add Yahoo as a preferred source to see more of our stories on Google. In a large clinical trial assessing Apretude, ViiV Healthcare’s recently approved injectable drug, as a form of HIV prevention, ...

Long-acting CAB+RPV is preferred by patients for ART due to reduced dosing frequency and stigma, with 89% switching after viral suppression. Studies like PILLAR and EBONI confirm the effectiveness and ...

One year ago, the United States approved a new injectable drug that prevents HIV. After successful clinical trials, long-acting cabotegravir was found to be almost 100 per cent effective at preventing ...

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

The federal Food and Drug Administration has approved Apretude (extended-release cabotegravir), the first long-acting injectable option for HIV prevention. The shots, which are administered by a ...

Please provide your email address to receive an email when new articles are posted on . Injectable cabotegravir administered every 8 weeks was associated with approximately nine times fewer HIV ...

Please provide your email address to receive an email when new articles are posted on . Replacing daily oral PrEP with long-acting injectable PrEP could modestly decrease HIV incidence among men who ...